Alopecia News and Articles

Return to Library

Recent Alopecia News and Articles

• Slotervaart Hospital Details Research in Chemotherapy
• Investigators at Leiden University Medical Center Target Dermatology
• Research from University of Porto in Dermatology Provides New Insights
• Researchers from Kamineni Institute of Medical Sciences Detail New Studies and Findings in the Area of Genomics and Genetics
• Studies from University of Palermo Yield New Data on Dermatology
• Entia Files Nutrigenomics Patent for Hair, Skin, and Nails
• Investigators at St. Jude Children\'s Research Hospital Release New Data on Immunology
• Research from University of California Yields New Data on Life Science Research
• Northwestern University Publishes Research in Dermatology

---

Researchers' Work from Fukushima Medical University Focuses on Hematology Research

2013 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Hematology Research are presented in a new report. According to news originating from Fukushima, Japan, by NewsRx correspondents, research stated, "High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial."

Our news journalists obtained a quote from the research from Fukushima Medical University, "Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored."

According to the news editors, the research concluded: "Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen."

For more information on this research see: Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. International Journal of Hematology, 2012;96(5):624-630. International Journal of Hematology can be contacted at: Springer Japan Kk, Chiyoda First Bldg East, 3-8-1 Nishi-Kanda, Chiyoda-Ku, Tokyo, 101-0065, Japan. (Springer - www.springer.com; International Journal of Hematology - www.springerlink.com/content/0925-5710/)

The news correspondents report that additional information may be obtained from Y. Kameoka, Fukushima Med Univ, Dept. of Cardiol & Hematol, Fukushima, Japan.

Keywords for this news article include: Asia, Antineoplastics, Pharmaceuticals, Japan, Drugs, Therapy, Lymphoma, Oncology, Fukushima, Carboplatin, Hydrocarbons, Cyclophosphamide, Alkylating Agents, Mustard Compounds, Lymphatic Diseases, Stem Cell Research, Hematology Research, Phosphoramide Mustards, Organoplatinum Compounds, Immunoproliferative Disorders

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC